Slider
Slider

|

Slider

AG Manibusan joins bipartisan coalition in calling for fentanyl to remain a Schedule I drug

Local
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Office of the Attorney General) — CNMI Attorney General Edward Manibusan is part of a bipartisan coalition of all 56 attorneys general in calling for Congress to permanently classify fentanyl-related substances as Schedule I drugs.

In the letter, the attorneys general urge Congress to pass S. 2701, the Federal Initiative to Guarantee Health by Targeting or FIGHT Fentanyl Act, a bipartisan bill introduced by U.S. Sens. Rob Portman, R-Oh., and Joe Manchin, D-WV.Schedule I drugs are defined as drugs with no currently accepted medical use and a high potential for abuse.

The Drug Enforcement Administration issued a temporary scheduling order in February 2018 to schedule fentanyl-related substances that has allowed federal law enforcement authorities to bring criminal actions against individuals who manufacture, distribute or handle fentanyl-related substances. This scheduling order is set to expire less than two months from now on Feb. 6, 2020. The FIGHT Fentanyl Act codifies DEA precedent to schedule fentanyl-related substances.

The FIGHT Fentanyl Act will ensure law enforcement agencies and courts retain the tools needed to keep those who traffic in this deadly substance off the streets.

In the most recent data available from the Centers for Disease Control and Prevention, there were 72,000 drug- related deaths in the United States in 2017. Of those deaths, roughly 40 percent involved fentanyl or a fentanyl-related compound.

Attorneys general from every state, territory and the District of Columbia signed the letter.

With the support of every Attorney General, the National Association of Attorneys General or NAAG has chosen to endorse the legislation as one of its official policy positions. NAAG typically endorses around a dozen policies a year.


previous arrow
next arrow
Shadow
Slider

Read more articles

Visit our Facebook Page

previous arrow
next arrow
Shadow
Slider